Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 6/20 | 0.45 |
| ▸ | STAT1 | P42224 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743539 | 0.88 | CCNB2 (0.47) | TSHRPDE5ASTAT1CHRM4MAPK1 | |
| SCHEMBL6740772 | 0.88 | CHRM4 (0.56) | TSHRPDE5ASTAT1CHRM4MAPK1 | |
| SCHEMBL6739651 | 0.85 | KMT2A (0.47) | TSHRSTAT1MAPK1POLBGAA | |
| SCHEMBL6742318 | 0.82 | MRGPRX1 (0.52) | STAT1MAPK1GAABCHEMEN1 | |
| SCHEMBL6739846 | 0.82 | SMN1; SMN2 (0.56) | TSHRSTAT1MAPK1GAAAPP | |
| SCHEMBL6740970 | 0.82 | ALPL (0.43) | KMT2A | |
| SCHEMBL6745666 | 0.79 | MAPT (0.45) | TSHRMAPK1BCDIN3DPOLBMEN1 | |
| SCHEMBL6739468 | 0.76 | ALDH1A1 (0.48) | TSHRPDE5ASTAT1MAPK1POLB | |
| SCHEMBL6743052 | 0.75 | ESR1 (0.49) | MAPK1POLBGAAMEN1KMT2A | |
| SCHEMBL6870999 | 0.74 | TSHR (0.36) | TSHRMAPK1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818642-B2 | CAMPYLOBACTER INFECTION TREATMENT | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040152714-A1 | Benzylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-05 | — | — | US | disclosed |
| EP-1395594-A1 | NEW BENZYLAMINOPYRIMIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094832-A1 | NEW BENZYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152714-A1 | Benzylaminopyrimidines | DPYD, PGLS, TPMT | TSHR 2503/4885PDE5A 1557/4885STAT1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.